Psychiatric Adverse Events in Patients Taking Isotretinoin as Reported in a Food and Drug Administration Database From 1997 to 2017
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Isotretinoin is a highly effective medication for severe acne. Although no causal link between isotretinoin and psychiatric adverse effects has been established, widespread media reporting of depression and suicidality with use of isotretinoin have raised concerns in both patients and clinicians and generated numerous cases of costly litigation. OBJECTIVE: To evaluate reports of psychiatric adverse events associated with isotretinoin use submitted to the US Food and Drug Administration from January 1, 1997, through December 31, 2017. DESIGN, SETTING, AND PARTICIPANTS: This retrospective study evaluated reports of psychiatric adverse events with isotretinoin as the primary suspect drug in the US Food and Drug Administration's Adverse Event Reporting System from 1997 through 2017. Publicly available data on number of patients enrolled in the iPLEDGE program were used to calculate rates of completed suicide per 100 000 patients enrolled in iPLEDGE in 2009 and 2010. All data were analyzed between July 1, 2018, and January 31, 2019. MAIN OUTCOMES AND MEASURES: The main outcomes were frequency and type of psychiatric adverse events in patients taking isotretinoin. Secondary analyses were stratification by age and sex and evaluation of completed suicide rates. RESULTS: Between 1997 and 2017, 17 829 psychiatric adverse events with isotretinoin use were reported to the US Food and Drug Administration, with depressive disorders, emotional lability, and anxiety disorders reported most frequently. Of these events, 8936 (50.1%) were reported among men and 8362 (46.9%) among women; the sex of the individual was not reported for 531 events (3.0%). Of the 13 553 reports that included patient age, the mean (SD) age was 22.1 (8.6) years. More than half (52.5%) of all events occurred in 10- to 19-year-old individuals. Whereas depression and anxiety were reported equally between sexes, eating disorders were more common in females (58 of 85 [68.2%]), while attention-deficit/hyperactivity disorder (55 of 83 events [66.3%]) and completed suicides (290 of 368 [78.8%]) were more common in males. The rates of completed suicide were 8.4 and 5.6 suicides per 100 000 patients enrolled in iPLEDGE in 2009 and 2010, respectively. CONCLUSIONS AND RELEVANCE: Although depressive disorders and suicidality were frequently reported with isotretinoin use, these reports must be considered in the context of elevated rates of depression and suicide among patients with acne at large. These data suggest that the rate of completed suicide in patients taking isotretinoin may be lower than that of the general US population. Many psychiatric adverse events unrelated to depression and suicidality were also reported, but it is unclear if they were a result of isotretinoin therapy. Although no causal link between isotretinoin and psychiatric risk has been established, patients taking the drug appear vulnerable to psychiatric concerns. Mandated monthly iPLEDGE visits may provide an opportunity to screen patients for psychiatric conditions and improve outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gender Differences in ADHD: A Meta-Analysis and Critical Review
GAUB, M., & CARLSON, C. L. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199708000-00011 · Cited by 1,117
Sundstrom, A., Alfredsson, L., Sjolin-Forsberg, G., Gerden, B., Bergman, U., & Jokinen, J. (2010) · BMJ · doi:10.1136/bmj.c5812 · Cited by 184
Schrom, K., Nagy, T., & Mostow, E. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.02.1148 · Cited by 21
Cited by
Management of Acne Vulgaris: A Review
Eichenfield, D. Z., Sprague, J., & Eichenfield, L. F. (2021) · JAMA · doi:10.1001/jama.2021.17633 · Cited by 389
Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study
Xia, E., Han, J., Faletsky, A., Baldwin, H., Beleznay, K., Bettoli, V., Dréno, B., Goh, C. L., Stein Gold, L., Gollnick, H., et al. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.2044 · Cited by 40
Self-citationIsotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
Paljarvi, T., McPherson, T., Luciano, S., Herttua, K., & Fazel, S. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21049 · Cited by 31
Ugonabo, N., Love, E., Wong, P. W., Rieder, E. A., Orlow, S. J., Kim, R. H., & Nagler, A. R. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.01.107 · Cited by 25
Chen, Y.-H., Wang, W.-M., Chung, C.-H., Tsao, C.-H., Chien, W.-C., & Hung, C.-T. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.055 · Cited by 24
Metadata
- Authors
- Singer, S., Tkachenko, E., Sharma, P., Barbieri, J. S., & Mostaghimi, A.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-10-01
- Volume
- 155
- Issue
- 10
- Pages
- 1162
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W2953618443
- Cited by
- 73
- References
- 3
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychiatric Adverse Events in Patients Taking Isotretinoin as Reported in a Food and Drug Administration Database From 1997 to 2017. https://app.cochat.ai/papers/10.1001/jamadermatol.2019.1416
- The paper
- Singer, S., Tkachenko, E., Sharma, P., Barbieri, J. S., & Mostaghimi, A. (2019). Psychiatric Adverse Events in Patients Taking Isotretinoin as Reported in a Food and Drug Administration Database From 1997 to 2017. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2019.1416
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.